Overview

EASSI - Evaluation of the Safety of Self-Administration With Icatibant

Status:
Completed
Trial end date:
2011-06-22
Target enrollment:
Participant gender:
Summary
This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Collaborator:
Jerini AG
Treatments:
Bradykinin
Icatibant